Login / Signup

Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.

Rona YaegerDaisuke KotaniSebastián MondacaAparna R ParikhHideaki BandoEmily E Van SeventerHiroya TaniguchiHuiYong ZhaoClaire N ThantElisa de StanchinaNeal X RosenRyan B CorcoranTakayuki YoshinoZhan YaoHiromichi Ebi
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Response to EGFR antibody treatment in mCRCs with class 2 BRAF mutants is rare, while a large portion of CRCs with class 3 BRAF mutants respond. Patients with colorectal cancer with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment.See related commentary by Fontana and Valeri, p. 6896.
Keyphrases
  • metastatic colorectal cancer
  • wild type
  • small cell lung cancer
  • epidermal growth factor receptor
  • tyrosine kinase
  • combination therapy
  • drug induced